August 24th, 2021 | 11:27 CEST
BioNTech, Standard Lithium, Desert Gold - Before the breakout?
Table of contents:
"[...] We quickly learned that the tailings are high-grade, often as high as 20 grams of gold per tonne; because they are produced by artisanal miners, local miners who use outdated technology for gold production. [...]" Ryan Jackson, CEO, Newlox Gold Ventures Corp.
Desert Gold - The Tension is rising
At Desert Gold (ISIN: CA25039N4084), the tension is rising. Investors are waiting for the completion of the important drilling program at the gold explorer's SMSZ project. The project is surrounded by large mines and gold producers such as Barrick Gold and B2 Gold. Accordingly, the takeover fantasy is high in case of positive results. A gold deposit has already been located at the SMSZ project. The values are up to 6.28 g/t gold. At 410 sq km, the Mali property is the only non-producing area in the region. The last update was dated June 22, 2021, when Desert Gold had reported that more than 82% of the planned drill program of over 230 holes had been completed. Since then, investors have been eagerly awaiting new reports. Last year, investors were able to experience the dynamics that positive drilling results have on Desert Gold stock. The stock shot up from CAD 0.05 to as high as CAD 0.35. A consolidation followed to as low as CAD 0.12 by the end of October 2020. Since then, a sideways phase has formed between CAD 0.12 and CAD 0.23. Currently, the share is available for about CAD 0.13. It seems attractive, as large companies are already mining gold in the region and deposits have been located. Once all results are in, Desert Gold will hear a NI 43-101 resource estimate to further quantify the project's potential. And then maybe a big neighbor will strike.
Standard Lithium - Capital Increase on the way?
After the substantial price increases in lithium shares, investors had taken profits in the past week. Also, at Standard Lithium (ISIN CA8536061010). After the share could previously increase by more than 200%. Currently, the Company is working on a large lithium project in the US state of Arkansas. The latest company news over the weekend was that Standard Lithium had filed a preliminary short prospect with authorities in Canada. The "shelf prospectus" secures the Company's ability to issue shares or various other securities in an amount of up to USD 250,000,000 over 25 months. Investors reacted calmly to the announcement on Monday and the share was able to gain slightly. Because, in fact, initially, no capital measure should be pending. At the end of March, Standard Lithium had cash reserves of over CAD 30.26 million. In addition, a loan from German partner Lanxess was converted into shares. The favorable conditions for the lithium market are intact. Car manufacturers are regularly introducing new electric models. As a result, lithium demand should also increase strongly.
BioNTech - High-Flyer unstoppable
The consolidation of high-flyer BioNTech (ISIN: US09075V1026) also seems to be over, and the share started the new stock market week on a positive note. After the booster speculations in the past weeks, a first large order now follows. Reuters reported that Great Britain would buy 35 million additional doses of the COVID-19 vaccine from Pfizer/BioNTech. The doses are expected to be delivered starting in the second half of 2022. "As we continue to build up the wall of protection against COVID-19, we need to do everything we can to protect the country for the future - whether that is from the virus as we know it or from new variants," Reuters quoted British Health Minister Sajid Javid as saying. That makes it clear that demand for the COVID-19 vaccine will remain high in 2022 - contrary to what investors initially assumed. BioNTech should thus continue to earn handsomely in 2022. Such booster orders also increase the likelihood that analysts will have to raise their estimates for sales and profits from the Marburger in the coming years. And beyond that, there is still the possibility of a positive newsflow regarding the product pipeline. BioNTech, for example, is working on individualized neoantigen TCR cell therapies for solid tumors and a vaccine against the dangerous tropical disease malaria, among others.
Consolidation over? It seems to be the case again for BioNTech and Standard Lithium. Desert Gold shareholders should also be happy about a rising share price in case of positive drill results.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.